OA07_JSW_Completers_PressRelease
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
13 nov. 2023 06h00 HE | Biosplice Therapeutics, Inc.
Biosplice Therapeutics Inc. presents results of OA-07 Long-Term Extension Trial for its knee OA drug candidate, lorecivivint.
OASIS Demographics and Wet AMD History
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
09 nov. 2022 07h05 HE | Clearside Biomedical, Inc.
- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...
logo color s and clearside.jpg
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
08 nov. 2022 16h05 HE | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Cornerstone Logo 3.jpg
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
03 août 2022 08h00 HE | Cornerstone Pharmaceuticals
CRANBURY, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Cornerstone_Pharma_Logo_V (1).png
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
16 juin 2022 14h14 HE | Cornerstone Pharmaceuticals, Inc.
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Certara Logo White Background.png
Certara Announces Release of Pinnacle 21 Enterprise Software
13 déc. 2021 08h00 HE | Certara
PRINCETON, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates...
Biosplice logo_final RGB 300 dpi_white background.png
Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis
26 avr. 2021 09h15 HE | Biosplice Therapeutics, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Syneos Health_rgb_r.jpg
Syneos Health Partners with Medable, Expanding Decentralized Solutions to Bring Clinical Trials Closer to the Patient
20 avr. 2021 09h00 HE | Syneos Health, Inc.
MORRISVILLE, N.C. and PALO ALTO, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Medable, the leading...
Syneos Health_rgb_r.jpg
Syneos Health and Protocol First Partner to Accelerate Collection and Review of Clinical Trial Data
24 févr. 2021 09h00 HE | Syneos Health, Inc.
MORRISVILLE, N.C. and SALT LAKE CITY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Protocol First, Inc., a...
cmed-logo_no tagline_png.png
New app optimizes home visits for virtual clinical trials
06 mai 2020 03h00 HE | Cmed
HORSHAM, United Kingdom, May 06, 2020 (GLOBE NEWSWIRE) -- Cmed Technology announces the encapsia Home Visit app to capture and manage clinical trial data from patients at home or in the community....